Can a patient with a history of supraventricular tachycardia take cyclobenzaprine (Flexeril)?

Can a Patient with History of SVT Take Flexeril?

Cyclobenzaprine (Flexeril) can be used cautiously in patients with a history of SVT, but it carries cardiac risks due to its structural similarity to tricyclic antidepressants and should be avoided if safer alternatives exist for muscle spasm management.

Key Cardiac Concerns

Cyclobenzaprine is structurally related to tricyclic antidepressants (amitriptyline, imipramine), and the FDA label explicitly warns that tricyclic antidepressants have been reported to produce arrhythmias, sinus tachycardia, and prolongation of conduction time 1. This is particularly relevant for SVT patients because:

• Sodium channel blockade: Case reports demonstrate that cyclobenzaprine can cause QRS prolongation and terminal right axis deviation, suggesting sodium channel blockade that contributed to cardiac arrest when combined with other medications 2
• Proarrhythmic potential: While cardiac toxicity from cyclobenzaprine alone is rare, it has documented potential for ventricular dysrhythmias 2
• Tachycardia risk: The atropine-like (anticholinergic) action of cyclobenzaprine can increase heart rate, which could theoretically trigger SVT episodes in susceptible patients 1

Clinical Decision Algorithm

If the patient has well-controlled SVT (no recent episodes, on stable therapy or post-ablation):

• Cyclobenzaprine may be used for short-term muscle spasm relief (typically 2-3 weeks maximum)
• Start with the lowest dose (5 mg) and monitor for palpitations or arrhythmia symptoms
• Ensure the patient is not on other medications that increase cardiac risk

If the patient has active/frequent SVT episodes or is on multiple cardiac medications:

• Avoid cyclobenzaprine and use alternative muscle relaxants (methocarbamol, tizanidine) or non-pharmacologic approaches
• The risk-benefit ratio does not favor cyclobenzaprine in unstable cardiac patients

Critical Drug Interactions to Screen

Before prescribing cyclobenzaprine to any SVT patient, verify they are NOT taking:

• Verapamil or diltiazem: These calcium channel blockers are first-line SVT treatments 3, but verapamil specifically can cause serotonin syndrome when combined with cyclobenzaprine 1
• SSRIs, SNRIs, or TCAs: Multiple case reports document serotonin syndrome with these combinations 4, which includes tachycardia as a key feature
• MAO inhibitors: This is an absolute contraindication with potentially life-threatening interactions 1

Common Pitfalls to Avoid

1. Assuming "muscle relaxants are safe": Cyclobenzaprine is NOT a benzodiazepine and carries distinct cardiac risks that many clinicians underappreciate
2. Polypharmacy blindness: The combination of therapeutic doses of cyclobenzaprine with other sodium channel blockers or serotonergic agents can precipitate serious cardiac events 2
3. Ignoring anticholinergic effects: The tachycardia from anticholinergic properties may be mistaken for SVT recurrence, leading to unnecessary escalation of antiarrhythmic therapy

Practical Recommendation

For a stable SVT patient requiring muscle spasm treatment, consider alternatives first (physical therapy, NSAIDs, methocarbamol). If cyclobenzaprine is deemed necessary, use the lowest effective dose (5 mg), limit duration to 2-3 weeks, counsel the patient to report palpitations immediately, and ensure no interacting medications are present. The FDA labeling supports cautious use with monitoring rather than absolute contraindication 1, but clinical judgment should weigh whether the musculoskeletal benefit justifies the cardiac risk in each individual case.